NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has announced new data for its ExoPTEN nanodrug, demonstrating significant progress towards commercial-grade manufacturing. The study focused on ExoPTEN's ability to target inflammation and injury sites when loaded with small interfering RNA (siRNA) produced by a new GMP-compliant manufacturer.
Key findings include:
- ExoPTEN showed exceptional homing capacity to injured spinal cord tissue in rats
- High concentration of the drug was observed in damaged tissue
- Results validate the quality of siRNA from the new GMP Partner
- Confirms NurExone's exosomes as an effective drug delivery system
This advancement marks a important step towards meeting quality and regulatory standards for commercial manufacturing, as the company progresses towards clinical trials.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) ha annunciato nuovi dati per il suo nanodrug ExoPTEN, dimostrando progressi significativi verso la produzione di grado commerciale. Illo studio si è concentrato sulla capacità di ExoPTEN di indirizzare l'infiammazione e i siti di lesione quando caricato con RNA interferente piccolo (siRNA) prodotto da un nuovo produttore conforme alle GMP.
I risultati chiave includono:
- ExoPTEN ha mostrato un'eccezionale capacità di oming nel tessuto del midollo spinale danneggiato nei ratti
- In alte concentrazioni, è stata osservata la presenza del farmaco in tessuti danneggiati
- I risultati convalidano la qualità del siRNA fornito dal nuovo Partner GMP
- Conferma gli esosomi di NurExone come un efficace sistema di consegna del farmaco
Questo progresso segna un passo importante per soddisfare gli standard di qualità e normativi per la produzione commerciale, mentre l'azienda avanza verso sperimentazioni cliniche.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) ha anunciado nuevos datos para su nanofármaco ExoPTEN, demostrando avances significativos hacia la producción de grado comercial. El estudio se centró en la capacidad de ExoPTEN para dirigir la inflamación y los sitios de lesión cuando está cargado con ARN interferente pequeño (siRNA) producido por un nuevo fabricante que cumple con las GMP.
Los hallazgos clave incluyen:
- ExoPTEN mostró una excepcional capacidad de localización en el tejido dañado de la médula espinal en ratas
- Se observó una alta concentración del fármaco en tejido dañado
- Los resultados validan la calidad del siRNA del nuevo socio GMP
- Confirma los exosomas de NurExone como un sistema de entrega de fármacos efectivo
Este avance marca un paso importante hacia el cumplimiento de los estándares de calidad y regulatorios para la fabricación comercial, mientras la empresa avanza hacia ensayos clínicos.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF)는 상업적 품질 제조를 위한 상당한 진전을 보여주는 새로운 ExoPTEN 나노약물 데이터를 발표했습니다. 연구는 새로운 GMP 준수 제조업체가 생산한 작은 간섭 RNA(siRNA)에 로드된 경우 ExoPTEN이 염증 및 손상 부위를 표적하는 능력에 중점을 두었습니다.
주요 발견 사항은 다음과 같습니다:
- ExoPTEN은 쥐의 손상된 척수 조직에 대한 예외적인 탐색 능력을 보여주었습니다.
- 손상된 조직에서 약물의 높은 농도가 관찰되었습니다.
- 결과는 새로운 GMP 파트너의 siRNA 품질을 검증합니다.
- NurExone의 엑소좀은 효과적인 약물 전달 시스템으로 확인됩니다.
이 발전은 상업적 제조를 위한 품질 및 규제 기준을 충족하기 위한 중요한 걸음을 의미하며, 회사는 임상 시험을 향해 나아가고 있습니다.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) a annoncé de nouvelles données sur son nanomédicament ExoPTEN, montrant des progrès significatifs dans la fabrication à des normes commerciales. L'étude s'est concentrée sur la capacité d'ExoPTEN à lorsqu'il est chargé avec de l'ARN interférent petit (siRNA) produit par un nouveau fabricant conforme aux GMP.
Les résultats clés incluent :
- ExoPTEN a montré une capacité d'atteinte exceptionnelle dans les tissus endommagés de la moelle épinière chez les rats
- Une forte concentration du médicament a été observée dans les tissus endommagés
- Les résultats valident la qualité du siRNA du nouveau partenaire GMP
- Confirme les exosomes de NurExone comme un système de livraison de médicaments efficace
Cette avancée marque une étape importante vers le respect des normes de qualité et réglementaires pour la fabrication commerciale, alors que l'entreprise avance vers des essais cliniques.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) hat neue Daten zu seinem ExoPTEN Nanodrug veröffentlicht, die bedeutende Fortschritte in Richtung einer kommerziellen Herstellung zeigen. Die Studie konzentrierte sich auf die Fähigkeit von ExoPTEN, Entzündungen und Verletzungsstellen zu targetieren, wenn sie mit kleinem interferierendem RNA (siRNA) geladen ist, das von einem neuen GMP-konformen Hersteller produziert wurde.
Die wichtigsten Ergebnisse sind:
- ExoPTEN zeigte eine außergewöhnliche Zielgenauigkeit im verletzten Rückenmarksgewebe bei Ratten
- Eine hohe Konzentration des Medikaments wurde in beschädigtem Gewebe beobachtet
- Die Ergebnisse bestätigen die Qualität des siRNA vom neuen GMP-Partner
- Bestätigt die Exosomen von NurExone als ein effektives Medikamentenabgabesystem
Dieser Fortschritt markiert einen wichtigen Schritt in Richtung der Einhaltung von Qualitäts- und Regulierungsstandards für die kommerzielle Herstellung, während das Unternehmen auf klinische Studien hinarbeitet.
- ExoPTEN demonstrated exceptional homing capacity to injured spinal cord tissue
- Successful transfer to a commercial manufacturer for siRNA production
- Validation of NurExone's exosomes as an effective drug delivery system
- Progress towards meeting quality and regulatory standards for commercial manufacturing
- None.
Study validates siRNA produced by new GMP-compliant Manufacturer and Company’s Exosomes for Drug Delivery
TORONTO and HAIFA, Israel, Aug. 09, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce new data for its ExoPTEN nanodrug, marking a significant step towards commercial-grade manufacturing. Building on the announcement of a new Good Manufacturing Practice (“GMP”) compliant Contract Research Organization (“CRO”) partner, this study assessed the performance of ExoPTEN loaded with small interfering RNA (“siRNA”) produced by the new manufacturer (the “GMP Partner”).
This study focused on the capability of ExoPTEN to biologically target sites of inflammation and injury as evidenced by a high concentration of the drug in damaged tissue. ExoPTEN, loaded with siRNA either from the GMP Partner or from a research grade CRO, was minimally-invasively administered to rats after spinal cord compression injury. The treated rats were compared to each other and to an untreated control group. The homing capacity of ExoPTEN was assessed by evaluating biodistribution of the ExoPTEN three days post-injury and injection.
As shown in Figure 1 below, ExoPTEN loaded with siRNA from both sources (A and C) demonstrated exceptional homing capacity to the injured spinal cord, targeting the site of inflammation with precision. This resulted in a high concentration of the drug in damaged tissue, further validating the quality of the siRNA produced by the Company’s GMP Partner and the use of NurExone’s exosomes as a drug delivery system.
“We are excited by the successful results of the highly complex transfer to a commercial manufacturer,” commented Dr. Noa Avni, Director of Research and Development. “These positive results reinforce our confidence in our ability to produce and scale up our siRNA to meet the quality and regulatory standards needed for commercial manufacturing. It also shows the scalability and reliability of our therapies as we advance towards clinical trials,” Dr. Avni added.
Dr. Lior Shaltiel, CEO of NurExone, also noted, “The ability of our loaded exosomes to precisely target sites of inflammation underscores their potential as an ideal and natural choice for drug delivery. We continue to be enthused by the progress we are observing.”
Figure 1: Homing ability of ExoPTEN using exosomes loaded with siRNA manufactured from a GMP-Compliant Manufacturer
About NurExone Biologic Inc.
NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”) listed pharmaceutical company that is developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the success of the partnership with the GMP Partner; the Company making progress in its new study focused on the capability of the ExoPTEN exosomes loaded with siRNA; the results of the study and implications of the study; the Company’s ability to produce and scale up the siRNA; the exosomes becoming an ideal and natural choice for drug delivery; the GMP Partner partnership helping NurExone continue its development of its ExoPTEN nanodrug, which it hopes to use to treat central nervous system injuries; and the homing capacity of the ExoPTEN exosomes loaded with siRNA.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; the partnership with the GMP manufacturer having the intended impact on the Company and its business; the patents safeguarding NurExone’s technology; the Company’s drug products having its intended benefits and effects; the Company making progress through new partnerships and technologies to move towards commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; the ExoPTEN exosomes loaded with siRNA having its intended benefits; the Company producing and scaling up the siRNA; the exosomes becoming an ideal and natural choice for drug delivery; the GMP Partner partnership helping NurExone continue its development of its ExoPTEN nanodrug, which it hopes to use to treat central nervous system injuries; and the NurExone platform technology offering novel solutions to drug companies.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the NurExone platform technology being unable to offer novel solutions to drug companies; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon partnership with the new GMP Partner; the Company’s inability to produce and scale up the siRNA; risk that the exosomes will not become an ideal and/or natural choice for drug delivery; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb1151ae-3090-459c-b44b-86ae3166c303
FAQ
What is the significance of NurExone's ExoPTEN nanodrug study results?
How does ExoPTEN target injured tissue in spinal cord injuries?
What progress has NurExone (NRXBF) made towards commercial manufacturing?
What are the potential implications of NurExone's ExoPTEN study for drug delivery?
